India’s Aurobindo Pharma posts third-quarter profit drop on higher expenses
Indian drugmaker Aurobindo Pharma reported a lower third-quarter profit on Thursday, as a spike in expenses more than offset strong demand for its generic drugs.
Related Articles
US spy plane is caught making mysterious trip to cartel stronghold
A US spy plane flew over the Gulf of California in Mexico this week. The purpose of the flight is unusual, but it comes at…
New name for lifesaving procedure recognizes Black pioneer’s role
Vivien Thomas helped develop what’s long been known as the Blalock-Taussig shunt. More prominent recognition of his vital contribution is way overdue.
International Stroke Congress (ISC) Articles | JAMA Network
International Stroke Congress (ISC) Articles | JAMA Network International Stroke Conference (ISC) QUICK LINKS: Visit Us at ISC For Authors More Articles QUICK LINKS Visit…
International Stroke Congress (ISC) Articles | JAMA Network
International Stroke Congress (ISC) Articles | JAMA Network International Stroke Conference (ISC) QUICK LINKS: Visit Us at ISC For Authors More Articles QUICK LINKS Visit…
Closing the Gap: Prepping Younger Med Students for Clinic
There’s a nationwide effort to better prepare undergrad medical students for the clinical experience.
Could This Be the End of PEPFAR?
Short email from a longtime colleague, working in Africa at a PEPFAR site: Without USAID, PEPFAR is essentially dead. I got chills reading this. PEPFAR, the abbreviation for…
Providers see hospital-at-home growth potential in cancer care
Mayo Clinic, Mount Sinai and Huntsman Cancer Insitute are delivering services from chemotherapy to imaging in cancer patients’ homes.
The CRISPR companies are not OK
Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably.
EurekAlert! Science News Service from AAAS
EurekAlert! is an online science news service featuring health, medicine, science and technology news from leading research institutions and universities. Sponsored by AAAS, the science…
Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries
Objective Quantify insulin glargine prices following the market introduction of biosimilars. Examine price levels and price changes for originator and biosimilars, by country. Methods Retrospective…
